The estimated Net Worth of Michele Greco is at least $607 Thousand dollars as of 24 August 2020. Ms. Greco owns over 5,000 units of Veru Inc stock worth over $83,675 and over the last 7 years she sold VERU stock worth over $0. In addition, she makes $523,098 as Chief Financial Officer and Chief Administrative Officer at Veru Inc.
Sign up
Ms. Greco VERU stock SEC Form 4 insiders trading
Michele has made over 2 trades of the Veru Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of VERU stock worth $13,250 on 24 August 2020.
The largest trade she's ever made was buying 20,000 units of Veru Inc stock on 20 August 2019 worth over $36,800. On average, Michele trades about 2,083 units every 31 days since 2018. As of 24 August 2020 she still owns at least 96,178 units of Veru Inc stock.
You can see the complete history of Ms. Greco stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michele Greco biography
Michele Greco CPA serves as Chief Financial Officer, Chief Administrative Officer of the Company. Ms. Greco has served as Chief Financial Officer of the Company since March 2018 and as Chief Administrative Officer of the Company since December 2017. Ms. Greco served as Executive Vice President of Finance of the Company from October 2016 to March 2018, Executive Vice President and Chief Financial Officer of the Company from December 2014 to October 2016 and Vice President and Chief Financial Officer of the Company from January 2013 to December 2014. Ms. Greco is a CPA with nearly 30 years of experience in public accounting with Ernst & Young LLP. From January 2011 to February 2012, Ms. Greco provided consulting services to Systems Research Incorporated as a recruiter of finance professionals. From March 2009 to January 2011, Ms. Greco was involved in series of personal business ventures. From 1994 to March 2009, Ms. Greco served as an audit partner with Ernst & Young LLP. Ms. Greco joined Ernst & Young LLP in 1981.
What is the salary of Michele Greco?
As the Chief Financial Officer and Chief Administrative Officer of Veru Inc, the total compensation of Michele Greco at Veru Inc is $523,098. There are 5 executives at Veru Inc getting paid more, with Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. having the highest compensation of $1,426,295.
How old is Michele Greco?
Michele Greco is 61, she's been the Chief Financial Officer and Chief Administrative Officer of Veru Inc since 2018. There are 5 older and 7 younger executives at Veru Inc. The oldest executive at Veru Inc is Mario Eisenberger, 70, who is the Independent Director.
What's Michele Greco's mailing address?
Michele's mailing address filed with the SEC is 2916 N. MIAMI AVENUE, SUITE 1000, MIAMI, FL, 33127.
Insiders trading at Veru Inc
Over the last 7 years, insiders at Veru Inc have traded over $5,672,221 worth of Veru Inc stock and bought 673,267 units worth $1,199,518 . The most active insiders traders include Mitchell Shuster Steiner, Harry Fisch, and K Gary Barnette. On average, Veru Inc executives and independent directors trade stock every 33 days with the average trade being worth of $22,682. The most recent stock trade was executed by Harry Fisch on 24 May 2024, trading 4,000 units of VERU stock currently worth $5,000.
What does Veru Inc do?
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
What does Veru Inc's logo look like?
Complete history of Ms. Greco stock trades at Veru Inc
Veru Inc executives and stock owners
Veru Inc executives and other stock owners filed with the SEC include:
-
Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.,
Chairman, Pres & CEO -
Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.S,
Chairman, Pres & CEO -
Mitchell Steiner,
Chairman of the Board, President, Chief Executive Officer -
Dr. Harry Fisch F.A.C.S., M.D.,
Vice Chairman & Chief Corp. Officer -
K Barnette,
Chief Scientific Officer -
Michele Greco,
Chief Financial Officer, Chief Administrative Officer -
Dr. K. Gary Barnette Ph.D.,
Chief Scientific Officer -
Dr. Harry Fisch,
Vice Chairman & Chief Corp. Officer -
Harry Fisch,
Vice Chairman of the Board, Chief Corporate Officer -
Michele Greco,
CFO & Chief Admin. Officer -
Mario Eisenberger,
Independent Director -
Jesus Socorro,
Independent Director -
Michael Rankowitz,
Independent Director -
Joel Batten,
Exec. VP & GM of Infectious Disease Franchise -
Dr. Gary Bird Ph.D.,
Exec. VP of Quality & Regulatory Affairs -
Dr. Domingo Rodriguez M.D.,
Exec. VP of Global Clinical Operations -
Phillip Kuhn,
Exec. VP of Strategy & Commercial -
Philip R. Greenberg,
Exec. VP & Gen. Deputy Counsel -
Dr. Robert H. Getzenberg Ph.D.,
Exec. VP for Medical Affairs -
Kevin J. Gilbert CPA, J.D.,
Exec. VP of Corp. Devel. -
Michael J. Purvis,
Exec. VP, Gen. Counsel & Corp. Strategy -
Samuel Fisch,
Exec. Director of Investor Relations & Corp. Communications -
Loren Mark Katzovitz,
Director -
Brian J. Groch,
Chief Commercial Officer -
Daniel Haines,
Chief Financial Officer -
Grace Hyun,
Director -
Charles T Jr Todd,
CEO of FHC Division -
O B Parrish,
Director -
Lucy Lu,
Director -
Robert Getzenberg,
Chief Scientific Officer -
Mary Margaret Frank,
Director -
David R Bethune,
Director